Pancreatic Cancer Research

ResearcherYokohama City University HospitalActive in the last 2 years

Atsushi Nakajima

Matched on ORCID iD 0000-0002-6263-1436; OpenAlex author ID A5002514925. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
2
Collaborators
22
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 10

  1. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulte… Co-author DOI 10.21873/anticanres.17215↗
  2. Maintaining early diagnosis of pancreatic adenocarcinoma in Japan: Local resilience against COVID-19. Last author DOI 10.1016/j.pan.2023.06.002↗
  3. Clinical Features and Prognostic Impact of Pancreatic Ductal Adenocarcinoma without Dilatation of the Main Pancreatic Duct: A Single-Center Retrospective Analy… Last author DOI 10.3390/diagnostics13050963↗
  4. Covered metallic stent placement for biliary drainage could be promising in the coming era of neoadjuvant chemo-radiation therapy for all pancreatic cancer. Last author DOI 10.1002/jhbp.958↗
  5. A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12051294↗
  6. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.pan.2018.11.001↗
  7. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine. Co-author DOI 10.1002/ijc.25437↗
  8. Usefulness of endoscopic biopsy using FOXP3+ Treg up-regulation in the duodenal papilla in the differential diagnosis between autoimmune pancreatitis and pancr… Last author DOI 10.1007/s00534-010-0359-0↗
  9. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.02053.x↗
  10. Covered stent placement for duodenal obstruction in pancreatic cancer. Co-author DOI 10.1159/000313695↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Noritoshi Kobayashi · 6 shared papers, 2011–2024 · strength 0.49
  2. Yusuke Kurita · 3 shared papers, 2019–2023 · strength 0.43
  3. Takuya Takayanagi · 2 shared papers, 2023 · strength 0.42
  4. Noriki Kasuga · 2 shared papers, 2023 · strength 0.42
  5. Itaru Endo · 4 shared papers, 2011–2021 · strength 0.34
  6. Yasushi Ichikawa · 2 shared papers, 2019–2024 · strength 0.30
  7. Kensuke Kubota · 5 shared papers, 2011–2021 · strength 0.29
  8. Motokazu Sato · 1 shared paper, 2024 · strength 0.20
  9. Sei Morinaga · 1 shared paper, 2024 · strength 0.20
  10. Robert M. Hoffman · 1 shared paper, 2024 · strength 0.20
  11. Sho Hasegawa · 1 shared paper, 2021 · strength 0.13
  12. Shin Yagi · 1 shared paper, 2021 · strength 0.13
  13. Shin Maeda · 3 shared papers, 2011–2020 · strength 0.13
  14. Toshio Fujisawa · 2 shared papers, 2011–2020 · strength 0.12
  15. Raj K. Puri · 2 shared papers, 2011–2020 · strength 0.12
  16. Yoshinori Ino · 1 shared paper, 2020 · strength 0.09
  17. Naoya Kato · 1 shared paper, 2020 · strength 0.09
  18. Hiroyuki Isayama · 1 shared paper, 2020 · strength 0.09
  19. Masahiko Inamori · 3 shared papers, 2011 · strength 0.06
  20. Shingo Kato · 2 shared papers, 2011 · strength 0.04
  21. Hiromi Kasugai · 1 shared paper, 2011 · strength 0.02
  22. Hitoshi Nakagama · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.